Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor‐infiltrating CD11b+ myelomonocytic cells

It is well established that cancer cells can recruit CD11b+ myeloid cells to promote tumor angiogenesis and tumor growth. Increasing interest has emerged on the identification of subpopulations of tumor‐infiltrating CD11b+ myeloid cells using flow cytometry techniques. In the literature, however, discrepancies exist on the phenotype of these cells (Coffelt et al., Am J Pathol 2010;176:1564–1576). Since flow cytometry analysis requires particular precautions for accurate sample preparation and trustable data acquisition, analysis, and interpretation, some discrepancies might be due to technical reasons rather than biological grounds. We used the syngenic orthotopic 4T1 mammary tumor model in immunocompetent BALB/c mice to analyze and compare the phenotype of CD11b+ myeloid cells isolated from peripheral blood and from tumors, using six‐color flow cytometry. We report here that the nonspecific antibody binding through Fc receptors, the presence of dead cells and cell doublets in tumor‐derived samples concur to generate artifacts in the phenotype of tumor‐infiltrating CD11b+ subpopulations. We show that the heterogeneity of tumor‐infiltrating CD11b+ subpopulations analyzed without particular precautions was greatly reduced upon Fc block treatment, dead cells, and cell doublets exclusion. Phenotyping of tumor‐infiltrating CD11b+ cells was particularly sensitive to these parameters compared to circulating CD11b+ cells. Taken together, our results identify Fc block treatment, dead cells, and cell doublets exclusion as simple but crucial steps for the proper analysis of tumor‐infiltrating CD11b+ cell populations. © 2010 International Society for Advancement of Cytometry

[1]  N. Ferrara,et al.  Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. , 2008, Cancer research.

[2]  H. Nariuchi,et al.  Fractionation of IgG, IgG2a, IgG2b and IgG3 immunoglobulins from mouse serum by protein A-sepharose column chromatography. , 1981, The Japanese journal of experimental medicine.

[3]  B. Thiele,et al.  Phenotypic investigation of mononuclear phagocytes by flow cytometry. , 1994, Journal of immunological methods.

[4]  G. Carulli Applications of flow cytometry in the study of human neutrophil biology and pathology. , 1996, Hematopathology and molecular hematology.

[5]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[6]  Michael C. Schmid,et al.  Myeloid cell trafficking and tumor angiogenesis. , 2007, Cancer letters.

[7]  W. Bolton,et al.  Comparison of cell viability probes compatible with fixation and permeabilization for combined surface and intracellular staining in flow cytometry. , 1995, Cytometry.

[8]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[9]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[10]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[11]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.

[12]  J. Hall,et al.  The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. , 1984, Journal of immunology.

[13]  Laurie Lamoreaux,et al.  Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. , 2006, Journal of immunological methods.

[14]  J. Talmadge,et al.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. , 2008, Blood.

[15]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[16]  J. Suttles,et al.  Functional plasticity of macrophages: in situ reprogramming of tumor‐associated macrophages , 2009, Journal of leukocyte biology.

[17]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[18]  M. Wong,et al.  Hematopoietic Stem Cells Contribute to Lymphatic Endothelium , 2008, PloS one.

[19]  S. Takeshita,et al.  Functional Association of CD9 with the Fcγ Receptors in Macrophages1 , 2001, The Journal of Immunology.

[20]  J F Leary,et al.  Doublet discrimination in DNA cell-cycle analysis. , 2001, Cytometry.

[21]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[22]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[23]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[24]  Fan Zhang,et al.  Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes , 2006, Nature Medicine.

[25]  Dingcheng Gao,et al.  The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. , 2009, Trends in molecular medicine.

[26]  D. Redelman,et al.  The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci , 2007, International journal of experimental pathology.

[27]  Gloria H Heppner,et al.  Nontransgenic models of breast cancer , 2000, Breast Cancer Research.

[28]  S. Takeshita,et al.  Functional association of CD9 with the Fc gamma receptors in macrophages. , 2001, Journal of immunology.

[29]  G. Christofori,et al.  Myeloid Cells Contribute to Tumor Lymphangiogenesis , 2009, PloS one.

[30]  Luigi Naldini,et al.  Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. , 2010, The American journal of pathology.

[31]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[32]  P. Sinha,et al.  Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression , 2005, Cancer Immunology, Immunotherapy.